CYP4F8

CYP4F8
Identifiers
AliasesCYP4F8, CPF8, CYPIVF8, cytochrome P450 family 4 subfamily F member 8
External IDsOMIM: 611545; MGI: 2146921; GeneCards: CYP4F8
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
1.14.14.1↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

11283

106648

Ensembl

ENSG00000186526

ENSMUSG00000073424

UniProt

P98187

n/a

RefSeq (mRNA)

NM_007253

NM_134127
NM_001346538

RefSeq (protein)

NP_009184

n/a

Location (UCSC)Chr 19: 15.62 – 15.63 MbChr 17: 32.9 – 32.92 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

Cytochrome P450 4F8 is a protein that in humans is encoded by the CYP4F8 gene.

Gene

This gene, CYP4F8, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and the synthesis of cholesterol, steroids, and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F3, is located approximately 18 kb away.

Tissue distribution

In addition to seminal vesicles, CYP4F8 is expressed in the kidney, prostate, epidermis, and corneal epithelium, and its mRNA has been detected in the retina. CYP4F8 is also greatly up-regulated in psoriatic skin.

Function

The CYP4F8 protein localizes to the endoplasmic reticulum and functions as a 19-hydroxylase of the arachidonic acid metabolite prostaglandin H2 (PGH2), and the Dihomo-γ-linolenic acid metabolite PGH1. These activities are particularly relevant in the seminal vesicles, where these metabolic pathways may influence local prostaglandin signaling.

In addition to its ability to metabolize and presumably thereby to inactivate or reduce the activity of PGH2 and PGH1, CYP4F8 adds hydroxyl residues to carbons 18 and 19 of arachidonic acid and Dihomo-γ-linolenic acid, CYP458 possesses epoxygenase activity in that it metabolizes the omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid, (EPA) to their corresponding epoxides, the epoxydocosapentaenoic acids (EDPs) and epoxyeicosatetraenoic acids (EEQs), respectively. The enzyme metabolizes DHA primarily to 19R,20S-epoxyeicosapentaenoic acid and 19S,20R-epoxyeicosapentaenoic acid isomers (termed 19,20-EDP) and EPA primarily to 17R,18S-eicosatetraenoic acid and 17S,18R-eicosatetraenoic acid isomers (termed 17,18-EEQ). 19-HETE is an inhibitor of 20-HETE, a broadly active signaling molecule which acts to constrict arterioles, elevate blood pressure, promote inflammation responses, and stimulates the growth of various types of tumor cells; however the in vivo ability and significance of 19-HETE in inhibiting 20-HETE has not been demonstrated (see 20-Hydroxyeicosatetraenoic acid). The EDPs (see Epoxydocosapentaenoic acid) and EEQs (see epoxyeicosatetraenoic acid) have a broad range of activities. In various animal models and in vitro studies on animal and human tissues, they decrease hypertension and pain perception; suppress inflammation; inhibit angiogenesis, endothelial cell migration and endothelial cell proliferation; and inhibit the growth and metastasis of human breast and prostate cancer cell lines. It is suggested that the EDP and EEQ metabolites function in humans as they do in animal models and that, as products of the omega-3 fatty acids, DHA acid and EPA, the EDP and EEQ metabolites contribute to many of the beneficial effects attributed to dietary omega-3 fatty acids. EDP and EEQ metabolites are short-lived, being inactivated within seconds or minutes of formation by epoxide hydrolases, particularly soluble epoxide hydrolase, and therefore act locally.

CYP4F8 has little activity in omega-hydroxylating leukotriene B4, prostaglandin D2, prostaglandin E2, prostaglandin E1, or prostaglandin F2.

The fatty acid metabolizing activity, including the ability to form epoxides, of CYP4F8 is very similar to that of CYP4F12. However, it and CYP4F12 are not regarded as being major contributors in forming the cited epoxides in humans although they might do so in tissues where they are highly expressed.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000186526 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000073424 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Bylund J, Finnström N, Oliw EH (July 1999). "Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles". Biochemical and Biophysical Research Communications. 261 (1): 169–174. Bibcode:1999BBRC..261..169B. doi:10.1006/bbrc.1999.1011. PMID 10405341.
  6. 1 2 "Entrez Gene: CYP4F8 cytochrome P450, family 4, subfamily F, polypeptide 8".
  7. ↑ Stark K, Wongsud B, Burman R, Oliw EH (Sep 2005). "Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8". Archives of Biochemistry and Biophysics. 441 (2): 174–181. doi:10.1016/j.abb.2005.07.003. PMID 16112640.
  8. 1 2 Johnson AL, Edson KZ, Totah RA, Rettie AE (2015). "Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer". Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer. Advances in Pharmacology. Vol. 74. pp. 223–262. doi:10.1016/bs.apha.2015.05.002. ISBN 978-0-12-803119-3. PMC 4667791. PMID 26233909.
  9. 1 2 Westphal C, Konkel A, Schunck WH (November 2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators. 96 (1–4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID 21945326.
  10. 1 2 Fleming I (October 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews. 66 (4): 1106–1140. doi:10.1124/pr.113.007781. PMID 25244930. S2CID 39465144.
  11. ↑ Zhang G, Kodani S, Hammock BD (January 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research. 53: 108–123. doi:10.1016/j.plipres.2013.11.003. PMC 3914417. PMID 24345640.
  12. ↑ He J, Wang C, Zhu Y, Ai D (December 2015). "Soluble epoxide hydrolase: A potential target for metabolic diseases". Journal of Diabetes. 8 (3): 305–313. doi:10.1111/1753-0407.12358. PMID 26621325.
  13. 1 2 Wagner K, Vito S, Inceoglu B, Hammock BD (October 2014). "The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling". Prostaglandins & Other Lipid Mediators. 113–115: 2–12. doi:10.1016/j.prostaglandins.2014.09.001. PMC 4254344. PMID 25240260.
  14. ↑ Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, et al. (March 2014). "Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway". Journal of Lipid Research. 55 (6): 1150–1164. doi:10.1194/jlr.M047357. PMC 4031946. PMID 24634501.
  15. ↑ Hardwick JP (Jun 2008). "Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases". Biochemical Pharmacology. 75 (12): 2263–2275. doi:10.1016/j.bcp.2008.03.004. PMID 18433732.

Further reading